AU4648197A - Peptides and peptidomimetics for inhibiting complement activation - Google Patents

Peptides and peptidomimetics for inhibiting complement activation

Info

Publication number
AU4648197A
AU4648197A AU46481/97A AU4648197A AU4648197A AU 4648197 A AU4648197 A AU 4648197A AU 46481/97 A AU46481/97 A AU 46481/97A AU 4648197 A AU4648197 A AU 4648197A AU 4648197 A AU4648197 A AU 4648197A
Authority
AU
Australia
Prior art keywords
peptidomimetics
peptides
complement activation
inhibiting complement
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46481/97A
Inventor
John D. Lambris
Dimitrios Morikis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
University of Pennsylvania Penn
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute, University of Pennsylvania Penn filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of AU4648197A publication Critical patent/AU4648197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU46481/97A 1997-09-17 1997-09-17 Peptides and peptidomimetics for inhibiting complement activation Abandoned AU4648197A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/016850 WO1999013899A1 (en) 1997-09-17 1997-09-17 Peptides and peptidomimetics for inhibiting complement activation

Publications (1)

Publication Number Publication Date
AU4648197A true AU4648197A (en) 1999-04-05

Family

ID=22261695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46481/97A Abandoned AU4648197A (en) 1997-09-17 1997-09-17 Peptides and peptidomimetics for inhibiting complement activation

Country Status (2)

Country Link
AU (1) AU4648197A (en)
WO (1) WO1999013899A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833202C (en) * 2002-09-20 2017-08-01 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
WO2005118020A1 (en) * 2004-04-21 2005-12-15 Allvivo, Inc. Surface coating comprising bioactive compound
EP1739078A1 (en) 2005-05-30 2007-01-03 Jerini AG Antagonists of C5a-receptor
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
RU2474586C2 (en) 2005-11-28 2013-02-10 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Efficient compstatin analogues
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
WO2009005651A2 (en) 2007-06-29 2009-01-08 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
AU2009215846B2 (en) 2008-02-19 2014-08-14 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
EP2331113A4 (en) 2008-08-20 2012-03-14 Univ Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
CA2738930C (en) 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
WO2010127336A1 (en) * 2009-05-01 2010-11-04 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20140113874A1 (en) 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
WO2012135624A1 (en) 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
JP6249949B2 (en) 2011-09-07 2017-12-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Compstatin analogs with improved pharmacokinetic properties
SI3660033T1 (en) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP6968787B2 (en) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. Dosing regimen
KR20190139931A (en) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 Dosage regimens and related compositions and methods
RU2020128624A (en) * 2018-02-27 2022-03-28 Зп Спв 3 К/С COMPSTATIN ANALOGUES AND THEIR MEDICAL APPLICATIONS
MX2020010520A (en) 2018-04-06 2021-01-15 Univ Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties.
EP4021921A1 (en) 2019-08-27 2022-07-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
MX2023000679A (en) 2020-07-16 2023-04-18 Zp Spv 3 K/S Inhibitors of complement factor c3 and their medical uses.

Also Published As

Publication number Publication date
WO1999013899A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
AU4648197A (en) Peptides and peptidomimetics for inhibiting complement activation
AU2203197A (en) Novel peptides which inhibit complement activation
AU2972097A (en) Peptide derivatives
AU2347397A (en) Azatide peptidomimetics
AU4394396A (en) Modified peptides
AU1803597A (en) Peptide derivatives
AU5347798A (en) Sealing arrangement
AU2131195A (en) Prophenins - antibiotic peptides
GB9718110D0 (en) Peptides
AU5061698A (en) Peptide derivatives
AU1725299A (en) Antifungal and antibacterial peptides
AU1999999A (en) Contryphan peptides
GB9714276D0 (en) Peptides and related compounds
GB9700154D0 (en) Peptides
AU5764898A (en) Multiple branch peptide constructions
AU5654096A (en) Antisense peptides
AUPM489194A0 (en) Peptides
EP0996457A4 (en) Fsh-releasing peptides
AU5161296A (en) Anti-haemorrhagic peptides
AU7162698A (en) Dipeptide surrogates containing asparagine-derived tetrahydropyrimidinones
AUPO507197A0 (en) Peptide polymers
AU9109098A (en) Hypusine peptides
AU4406197A (en) Cysteine containing peptides
AU1487095A (en) Peptides for inhibiting pepsin release
AUPO324096A0 (en) Linker peptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase